Melan – A/MART – 1 Peptide

Product Description

Melan – A/MART – 1 Peptide
Catalog number: B2012804
Lot number: Batch Dependent
Expiration Date: Batch dependent
Amount: 500 ug
Molecular Weight or Concentration: N/A
Supplied as: Lyophilized Powder
Applications: molecular tool for various biochemical applications
Storage: 2-8°C
Keywords: Melan – A/MART – 1 (24 – 34)
Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um.

References:
1: Tarbe M, Miles JJ, Edwards ESJ, Miles KM, Sewell AK, Baker BM, Quideau S. Synthesis and Biological Evaluation of Hapten-Clicked Analogues of The Antigenic Peptide Melan-A/MART-1(26(27L)-35) ChemMedChem. 2020 May 6;15(9):799-807.
2: Tiwari R, Geliebter J, Lucchese A, Mittelman A, Kanduc D. Computational peptide dissection of Melan-a/MART-1 oncoprotein antigenicity Peptides. 2004 Nov;25(11):1865-71.
3: Romero P, Speiser DE, Rufer N. Deciphering the unusual HLA-A2/Melan-A/MART-1-specific TCR repertoire in humans Eur J Immunol. 2014 Sep;44(9):2567-70.
4: Bettinotti MP, Kim CJ, Lee KH, Roden M, Cormier JN, Panelli M, Parker KK, Marincola FM. Stringent allele/epitope requirements for MART-1/Melan A immunodominance: implications for peptide-based immunotherapy J Immunol. 1998 Jul 15;161(2):877-89.
5: Zarour HM, Kirkwood JM, Kierstead LS, Herr W, Brusic V, Slingluff CL Jr, Sidney J, Sette A, Storkus WJ. Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells Proc Natl Acad Sci U S A. 2000 Jan 4;97(1):400-5.
6: Hofbauer GF, Kamarashev J, Geertsen R, Böni R, Dummer R. Melan A/MART-1 immunoreactivity in formalin-fixed paraffin-embedded primary and metastatic melanoma: frequency and distribution Melanoma Res. 1998 Aug;8(4):337-43.
7: Bioley G, Jandus C, Tuyaerts S, Rimoldi D, Kwok WW, Speiser DE, Tiercy JM, Thielemans K, Cerottini JC, Romero P. Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers J Immunol. 2006 Nov 15;177(10):6769-79.
8: Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, Rosenberg SA. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired Blood. 2009 Aug 20;114(8):1537-44.
9: Balasse E, Gatouillat G, Patigny D, Andry MC, Madoulet C. In vivo anti-melanoma activities of the Melan-A/MART-1(101-115) T CD4+ cell peptide Vaccine. 2009 Oct 19;27(44):6107-9.
10: Lienard D, Avril MF, Le Gal FA, Baumgaertner P, Vermeulen W, Blom A, Geldhof C, Rimoldi D, Pagliusi S, Romero P, Dietrich PY, Corvaia N, Speiser DE. Vaccination of melanoma patients with Melan-A/Mart-1 peptide and Klebsiella outer membrane protein p40 as an adjuvant J Immunother. 2009 Oct;32(8):875-83.

Products Related to Melan – A/MART – 1 Peptide can be found at Peptides